Company Announcements

Board Committee Membership

Source: RNS
RNS Number : 8443X
Smith & Nephew Plc
01 September 2022

1 September 2022



Board Committee Membership


Smith & Nephew plc (LSE:SN, NYSE:SNN) announces that the Board has resolved to appoint Jo Hallas, Independent Non-Executive Director, as a member of the Audit Committee and Angie Risley, Independent Non-Executive Director, as a member of the Nomination & Governance Committee. Both appointments are effective 1 September 2022.


This announcement has been made in accordance with the requirements of 9.6.11(3) of the Listing Rules.





Andrew Swift

+44 (0) 1923 477433





Charles Reynolds

+44 (0) 1923 477314




Susan Gilchrist / Ayesha Bharmal

+44 (0) 20 7404 5959





About Smith+Nephew


Smith+Nephew is a portfolio medical technology company that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.


Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.


For more information about Smith+Nephew, please visit and follow us on Twitter, LinkedIn, Instagram or Facebook.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.